Biogen's diranersen Alzheimer's extension showed 38% benefit at week 96, a 1.09-point CDR-SB difference; CELIA missed its 76-week endpoint.
Biogen recently shared new clinical, biomarker and safety data on its Alzheimer’s portfolio at the CTAD 2026 conference, including extended Phase 2 CELIA results for diranersen and long term analyses for lecanemab. The breadth of readouts, from 96 week diranersen extension data to real world lecanemab evidence, highlights how Alzheimer’s programs are shaping Biogen’s future treatment mix and operational focus. We will now look at how Biogen’s investment narrative could be influenced by the...
Tipranks Press Release.
Biogen (BIIB) has swung back to growth as shown by its solid Q3 results, RBC analysts wrote in a not
Motley Fool Press Release.
Biogen crushed third-quarter expectations early Tuesday, helped by its suite of newer products and leading to a guidance hike.
The biotechnology company said the swing to a loss was primarily due to transaction-related charges.
Biogen is leaning on newer drugs, including recently acquired assets, as its multiple sclerosis franchise faces ongoing competition.
This is the newest page. Registered accounts read further back.